Fig. 7

Activated fibroblasts by exosomal linc00881 accelerate OS progression. A. IL-6 secretion from HFL-1 treated by exosomes from two OS cells was detected via ELISA assay. B. IL-6 secretion from HFL-1 treated by exosomes from two OS cells or exosomes from linc00881 interrupted two OS cells and was detected via ELISA assay. C. Spheroid formation ability of MG63 treated with indicated CM. Representative Images and quantitative analysis were shown.100 × . D–E. Spheroid formation ability of MG63 treated with CM containing: a. IL-6 neutralizing antibody, b. IgG control antibody, c. linc00881 siRNA exo, d. IL-6 neutralizing antibody plus linc00881 siRNA exo. Representative Images and quantitative analysis were shown.100 × . F. Spheroid formation ability of HOS treated with indicated CM. Representative Images and quantitative analysis were shown.100 × . G. Spheroid formation ability of MG63 treated with CM as indicated in D. Representative Images and quantitative analysis were shown.100 × . H. Migration assay of MG63 treated with indicated CM. Representative Images and quantitative analysis were shown.100 × . I. Migration assay of MG63 treated with indicated CM indicate in D. Representative Images and quantitative analysis were shown.100 × . J, K. Migration assay of HOS treated with indicated CM. Representative Images and quantitative analysis were shown.100 × . L. Migration assay of HOS treated with CM indicated in D. Representative Images and quantitative analysis were shown.100 × . M, N. Western blotting analysis of the expression of MMP2 in MG63 and HOS cells treated with indicated CM. (*p < 0.05; **p < 0.01; *** p < 0.0001)